Section 4: Clinical Pharmacy Services 2021
DOI: 10.1136/ejhpharm-2021-eahpconf.163
|View full text |Cite
|
Sign up to set email alerts
|

4CPS-331 Inflammatory parameter analysis in severe COVID-19 patients treated with tocilizumab

Abstract: change with same therapeutic target (SWITCH) and drug change with different therapeutic target (SWAP). The Studentś t test for correlated groups was performed but any intervention involving SWAP or SWITCH was excluded. Asymptomatic patients without altered APR and optimal plasma adalimumab concentrations maintained the same treatment scheme. Results 89 patients were analysed and 41 (46%) patients were proposed and accepted for interventions, of whom 22 (54%) were men with a mean age of 40 years (18-66). The da… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles